Market Place
Sourcing Support
Johnson & Johnson`s Balversa (Erdafitinib) Receives Approval in Europe
29 Aug 2024 //
EMA
EC Approves BALVERSA For Unresectable Or Metastatic Urothelial Carcinoma
23 Aug 2024 //
GLOBENEWSWIRE
CHMP Adopts Positive Opinion For BALVERSA To Treat Urothelial Carcinoma
28 Jun 2024 //
GLOBENEWSWIRE
J&J`s Balversa gets mixed label update in FDA approval conversion
22 Jan 2024 //
FIERCE PHARMA
First Results with Erdafitinib Intravesical Delivery System Show Clinical Activity in Bladder Cancer
22 Oct 2023 //
GLOBENEWSWIRE
Results from Phase 2 Study Showed Improved Rates of Survival in Bladder Cancer
21 Oct 2023 //
GLOBENEWSWIRE
Janssen Submits MAA to the EMA Seeking Approval of Erdafitinib
08 Sep 2023 //
GLOBENEWSWIRE
Janssen Submits sNDA to the USFDA Seeking Full Approval of BALVERSA for MUC
28 Aug 2023 //
PR NEWSWIRE
Erdafitinib Elicits Responses in FGFR-altered Solid Tumors
23 Aug 2023 //
ONCLIVE
FDA Confirms Paragraph IV Patent Litigation for Erdafitinib Tablets
15 Jun 2023 //
FDA
J&J`s Balversa wins out over chemo in bladder cancer study
06 Jun 2023 //
FIERCE PHARMA
Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy
05 Jun 2023 //
GLOBENEWSWIRE
Janssen Presents Initial Results from PII RAGNAR Study of BALVERSA
07 Jun 2022 //
PRNEWSWIRE
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
31 Jan 2022 //
GLOBENEWSWIRE
Janssen Presents Data from Phase 1b/2 NORSE Study
17 Sep 2021 //
BIOSPACE
After FDA rejection, Immunomedics tries again with breast cancer drug
04 Dec 2019 //
BIOPHARMA DIVE
U.K. drug discovery startup Healx taps GSK, Astex alum as CSO
11 Jul 2019 //
FIERCE BIOTECH
J&J’s targeted bladder cancer treatment gets US approval
15 Apr 2019 //
PMLIVE
BALVERSA™ (erdafitinib) Receives USFDA Approval for the Treatment of Patients
12 Apr 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.